CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
A phase 2 trial of Pembrolizumab in colorectal cancer, run by CytoDyn, Inc., active and no longer recruiting.
Overview
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen is a phase 2 interventional study registered as NCT06699836 by CytoDyn, Inc., with 66 participants enrolled, started 2025-06-16 and due to reach its primary completion in 2028-01. Interventions recorded: 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab. Conditions listed: Metastatic Colorectal Cancer (mCRC). No results are recorded here; the registry entry is the source.
Setting
A Phase Two Study Evaluating Two Doses of Leronlimab (PRO 140) In Combination With Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants With Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCRC)
Phase
Phase 2
Sponsor
CytoDyn, Inc.
Registry
Enrolled
66